EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSPREG00000005037
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSPREG00000020922
Gene Symbol: GUCY1A2
4 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSPREG00000004996
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSPREG00000008453
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSPREG00000014180
Gene Symbol: HSP90AA1.2
2 Cross references
345 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha 1

Ensembl ID : ENSPREG00000014113
Gene Symbol: LOC103457917
3 Cross references
330 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSPREG00000012015
Gene Symbol: LOC103474962
3 Cross references
509 Possible Orthologues:

High Mobility Group-T Protein

Ensembl ID : ENSPREG00000010391
Gene Symbol: LOC103475582
2 Cross references
511 Possible Orthologues:

Histamine H2 Receptor-Like

Ensembl ID : ENSPREG00000018736
Gene Symbol: LOC103471339
3 Cross references
189 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSPREG00000006524
Gene Symbol: HRH1
4 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSPREG00000001612
Gene Symbol: HRH2
3 Cross references
182 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSPREG00000019031
Gene Symbol: HDAC10
3 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).